Late-Onset Retinal Degeneration
Symptoms, Doctors, Treatments, Advances & More

Late-Onset Retinal Degeneration Overview

Save information for later
Sign Up

Learn About Late-Onset Retinal Degeneration

What is the definition of Late-Onset Retinal Degeneration?
Late-onset retinal degeneration is an inherited retinal dystrophy characterized by delayed dark adaptation and nyctalopia and drusen deposits presenting in adulthood, followed by cone and rod degeneration that presents in the sixth decade of life, which leads to central vision loss. Anterior segment features such as peripupillary iris transillumination defects and abnormally long anterior zonular insertions are also observed. Choroidal neovascularization and glaucoma may occur in the late stages of the disease.
What are the alternative names for Late-Onset Retinal Degeneration?
  • Late-onset retinal degeneration
  • Autosomal dominant late-onset retinal degeneration
  • LORD
  • Pigmentary retinopathy
  • Retinal degeneration, late-onset, autosomal dominant
Who are the top Late-Onset Retinal Degeneration Local Doctors?
Elite in Late-Onset Retinal Degeneration
Elite in Late-Onset Retinal Degeneration
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Philip Rosenfeld is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Rosenfeld is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Carotid Artery Surgery, and Vitrectomy. Dr. Rosenfeld is currently accepting new patients.

Elite in Late-Onset Retinal Degeneration
Dr. Glenn J. Jaffe
Ophthalmology | General Surgery
Elite in Late-Onset Retinal Degeneration
Dr. Glenn J. Jaffe
Ophthalmology | General Surgery
Referral may be required

Duke Eye Center

2351 Erwin Rd, 
Durham, NC 
919-681-3937
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Glenn Jaffe is an Ophthalmologist and a General Surgeon practicing medicine in Durham, North Carolina. Dr. Jaffe is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Vitrectomy, and Cataract Removal. Dr. Jaffe is board certified in American Board Of Ophthalmology, Ophthalmology. Dr. Jaffe is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Late-Onset Retinal Degeneration
Dr. Harry W. Flynn
Ophthalmology
Elite in Late-Onset Retinal Degeneration
Dr. Harry W. Flynn
Ophthalmology
Referral may be required
900 Northwest 17th Street, 
Miami, FL 
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Harry Flynn is an Ophthalmologist practicing medicine in Miami, Florida. Dr. Flynn is rated as an Elite provider by MediFind in the treatment of Late-Onset Retinal Degeneration. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Endophthalmitis, Retinal Detachment, Interstitial Keratitis, Vitrectomy, and Cataract Removal. Dr. Flynn is currently accepting new patients.

View All Doctors
What are the latest Late-Onset Retinal Degeneration Clinical Trials?
A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy
A Phase I/IIa Clinical Trial to Assess the Safety, Tolerability, and Efficacy of a Single Intravitreal Injection of SPVN20 Gene Therapy in Participants With Advanced Rod-Cone Dystrophy
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: Neovascular age-related macular degeneration (nAMD), also known as wet AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. The purpose of this study is to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD). Surabgene Lomparvovec (ABBV-RGX-314) i...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center